GSK: share up on favourable court ruling in Canada
(CercleFinance.com) - On Friday GSK welcomed the Canadian court's dismissal of a class action lawsuit filed in the Zantac case, which boosted the stock in London (+1.
7% at present).
The British biopharmaceutical company said that the British Columbia Supreme Court had ruled that a class action lawsuit brought by Canadian patients who took the heartburn drug previously marketed by GSK was inadmissible.
GSK said that the court's rationale for the ruling was the absence of evidence that ranitidine or the presence of an impurity (NDMA) caused cancer in humans.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
7% at present).
The British biopharmaceutical company said that the British Columbia Supreme Court had ruled that a class action lawsuit brought by Canadian patients who took the heartburn drug previously marketed by GSK was inadmissible.
GSK said that the court's rationale for the ruling was the absence of evidence that ranitidine or the presence of an impurity (NDMA) caused cancer in humans.
Copyright (c) 2023 CercleFinance.com. All rights reserved.